While promising, epigenetic drugs are not without risks. Their ability to alter gene expression across multiple tissues can lead to unintended side effects. For example, reactivating silenced genes in non-target tissues can potentially lead to toxicity or even carcinogenesis. Therefore, comprehensive safety assessments are essential during drug development.
